With the rapidly moving IO landscape, get right up to date with 2018 trial data with this free “Biomarkers in Immuno-Oncology Clinical Trials” overview.
Martin Tolar, Founder and CEO of Alzheon, discusses the crucial role patient stratification and diagnostics will have to play in the development of disease-modifying drugs for AD.
Jason Christiansen, Vice President, Diagnostics at Ignyta discuss the best way to co-develop drug and diagnostic and how to deliver the value of diagnostic testing to patients.
This white paper has been developed in collaboration with ANGLE plc. Liquid biopsy: Cells for Precision Medicine
J. Carl Barrett, VP, Translational Sciences Oncology, AstraZeneca
View the full report from the 2016 Companion Diagnostics Industry Survey
See what Mark Roberts from Covance has to say on perspectives on drug-companion diagnostic co-development.